Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts
- PMID: 12225436
- DOI: 10.1034/j.1399-0012.2002.02036.x
Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts
Abstract
Cyclosporine (CyA) trough concentrations are poor predictors for acute rejection post-transplant. Patients were part of a randomized trial of basiliximab (n=70) vs. anti-thymocyte globulin (ATGAM) (n=65), both in combination with Neoral, mycophenolate mofetil, and steroids, undergoing first or second, cadaveric or live donor renal transplants. Whole blood samples were collected just before (C0) and at 2 h after CyA dosing on day 4 and at the end of weeks 1, 2, 4, and 8. The CyA was measured by fluorescence polarization immunoassay (TDx). Mean CyA C0 and C2 concentrations were calculated. Logistic regression analysis revealed that mean C2 level was the only predictor of acute rejection (P < or = 0.001). Higher mean C2 levels predicted lower rejection probabilities. Linear regression analysis revealed that higher mean C2 levels were not related to higher serum creatinine levels at either week 4 or 24 or to incidence of headache or tremor. The CyA C2 levels predict the frequency of rejection postrenal transplant. Target C2 levels are in the range of 1500 ng/dL.
Similar articles
-
Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.Transplantation. 2001 Dec 27;72(12):1915-9. doi: 10.1097/00007890-200112270-00008. Transplantation. 2001. PMID: 11773888 Clinical Trial.
-
A single center's clinical experience with quadruple immunosuppression including ATG or IL2 antibodies and mycophenolate mofetil in simultaneous pancreas-kidney transplants.Clin Transplant. 2000 Aug;14(4 Pt 1):340-4. doi: 10.1034/j.1399-0012.2000.140410.x. Clin Transplant. 2000. PMID: 10945205 Clinical Trial.
-
Randomized, international study of cyclosporine microemulsion absorption profiling in renal transplantation with basiliximab immunoprophylaxis.Am J Transplant. 2002 Feb;2(2):157-66. doi: 10.1034/j.1600-6143.2002.020207.x. Am J Transplant. 2002. PMID: 12099518 Clinical Trial.
-
Basiliximab lowers the cyclosporine therapeutic threshold in the early post-kidney transplant period.Clin Transplant. 2005 Apr;19(2):225-9. doi: 10.1111/j.1399-0012.2005.00325.x. Clin Transplant. 2005. PMID: 15740559
-
Basiliximab: a review of its use as induction therapy in renal transplantation.Drugs. 2003;63(24):2803-35. doi: 10.2165/00003495-200363240-00009. Drugs. 2003. PMID: 14664658 Review.
Cited by
-
Preprandial C2 monitoring of cyclosporine treatment in children with nephrotic syndrome.Pediatr Nephrol. 2005 Sep;20(9):1359-60. doi: 10.1007/s00467-005-1932-7. Epub 2005 May 26. Pediatr Nephrol. 2005. PMID: 15918005 No abstract available.
-
[Significance of cyclosporin A absorption for effective immunomodulatory therapy after high-risk keratoplasty].Ophthalmologe. 2008 May;105(5):457-62. doi: 10.1007/s00347-007-1632-8. Ophthalmologe. 2008. PMID: 18299847 German.
-
Links between cyclosporin exposure in tissues and graft-versus-host disease in pediatric bone marrow transplantation: analysis by a PBPK model.Pharm Res. 2011 Mar;28(3):531-9. doi: 10.1007/s11095-010-0299-z. Epub 2010 Oct 21. Pharm Res. 2011. PMID: 20963627
-
Cyclosporine C2 monitoring for the treatment of frequently relapsing nephrotic syndrome in children: a multicenter randomized phase II trial.Clin J Am Soc Nephrol. 2014 Feb;9(2):271-8. doi: 10.2215/CJN.13071212. Epub 2013 Nov 21. Clin J Am Soc Nephrol. 2014. PMID: 24262503 Free PMC article. Clinical Trial.
-
Interleukin 2 receptor antagonists for kidney transplant recipients.Cochrane Database Syst Rev. 2010 Jan 20;2010(1):CD003897. doi: 10.1002/14651858.CD003897.pub3. Cochrane Database Syst Rev. 2010. PMID: 20091551 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous